Advanced search
Publication Cover
Journal of Medical Economics Volume 20, 2017 - Issue 12
Submit an article Journal homepage
499
Views
3
CrossRef citations to date
0
Altmetric
Cardiology

Predictors for total hospital and cardiology cost claims among patients with atrial fibrillation initiating dabigatran or acenocoumarol in The Netherlands

M. S. JacobsDepartment of Clinical Pharmacy and Toxicology, Martini Hospital, Groningen, The Netherlands; ;Unit of PharmacoTherapy, -Epidemiology & -Economics, Groningen Research Institute of Pharmacy (GRIP), University of Groningen, Groningen, The Netherlands; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-6185-4718
ORCID Icon,
M. W. J. van LeentUnit of PharmacoTherapy, -Epidemiology & -Economics, Groningen Research Institute of Pharmacy (GRIP), University of Groningen, Groningen, The Netherlands;
,
R. G. TielemanDepartment of Cardiology, Martini Hospital, Groningen, The Netherlands; ;Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands;
,
F. G. A. JansmanUnit of PharmacoTherapy, -Epidemiology & -Economics, Groningen Research Institute of Pharmacy (GRIP), University of Groningen, Groningen, The Netherlands; ;Department of Clinical Pharmacy, Deventer Hospital, Deventer, The Netherlands;
,
Q. CaoUnit of PharmacoTherapy, -Epidemiology & -Economics, Groningen Research Institute of Pharmacy (GRIP), University of Groningen, Groningen, The Netherlands;
,
M. J. PostmaUnit of PharmacoTherapy, -Epidemiology & -Economics, Groningen Research Institute of Pharmacy (GRIP), University of Groningen, Groningen, The Netherlands; ;Institute for Science in Healthy Aging & healthcaRE (SHARE), University Medical Center Groningen (UMCG), University of Groningen, Groningen, The Netherlands; ;Department of Epidemiology, University Medical Center Groningen (UMCG), University of Groningen, Groningen, The NetherlandsORCID Iconhttp://orcid.org/0000-0002-6306-3653
ORCID Icon &
M. van HulstDepartment of Clinical Pharmacy and Toxicology, Martini Hospital, Groningen, The Netherlands; ;Unit of PharmacoTherapy, -Epidemiology & -Economics, Groningen Research Institute of Pharmacy (GRIP), University of Groningen, Groningen, The Netherlands;
show all
Pages 1231-1236 | Received 19 Jun 2017, Accepted 01 Aug 2017, Published online: 22 Aug 2017

References

  • Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995;155:469-73
  • Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893-962
  • Wolowacz SE, Samuel M, Brennan VK, et al. The cost of illness of atrial fibrillation: a systematic review of the recent literature. Europace 2011;13:1375-85
  • United Nations, Department of Economic and Social Affairs, Population Division. World population prospects: The 2015 revision. New York (United States of America): UN; 2015
  • Ball J, Carrington MJ, McMurray JJ, et al. Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. Int J Cardiol 2013;167:1807-24
  • Friberg L, Rosenqvist M, Lindgren A, et al. High prevalence of atrial fibrillation among patients with ischemic stroke. Stroke 2014;45:2599-605
  • Miller CS, Grandi SM, Shimony A, et al. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol 2012;110:453-60
  • Xie L, Vo L, Keshishian A, et al. Comparison of hospital length of stay and hospitalization costs among patients with non-valvular atrial fibrillation treated with apixaban or warfarin: An early view. J Med Econ 2016;19:769-76
  • Deitelzweig S, Amin A, Jing Y, et al. Medical costs of oral anticoagulants vs warfarin for atrial fibrillation patients with different stroke risks. Cardiol Ther 2013;2:165-70
  • Bancroft T, Lim J, Wang C, et al. Health care resource utilization, costs, and persistence in patients newly diagnosed as having nonvalvular atrial fibrillation and newly treated with dabigatran versus warfarin in the United States. Clin Ther 2016;38:545-56.e1–6
  • Korenstra J, Wijtvliet EP, Veeger NJ, et al. Effectiveness and safety of dabigatran versus acenocoumarol in 'real-world' patients with atrial fibrillation. Europace 2016;18:1319-27
  • Dutch Healthcare Authority (NZa). Handleiding DBC-systematiek. Utrecht (The Netherlands): NZa; 2015
  • Min Y, Agresti A. Modeling nonnegative data with clumping at zero: a survey. JIRSS 2002;1:7-33
  • Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 2012;33:1500-10
  • Olesen JB, Lip GY, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011;342:d124
  • Francis K, Yu C, Alvrtsyan H, et al. Healthcare utilization and costs associated with dabigatran compared to warfarin treatment in newly diagnosed patients with non-valvular atrial fibrillation. Curr Med Res Opin 2015;31:2189-95
  • Center for Disease Control and Prevention. Age-adjusted percent distribution (with standard errors) of length of time since last contact with doctor or other health care professional among adults aged 18 and over, by selected characteristics. Summary Health Statistics Tables for U S Adults: National Health Interview Survey. Den Haag (The Netherlands): CDCP; 2014
  • Statistics Netherlands (CBS) Statline. Hospitalizations; gender, age, region and diagnosis-grouping ISHMT; 2012. http://statline.cbs.nl/. Accessed March 28, 2017
  • Ali AN, Howe J, Abdel-Hafiz A. Cost of acute stroke care for patients with atrial fibrillation compared with those in sinus rhythm. Pharmacoeconomics 2015;33:511-20
  • Lin HJ, Wolf PA, Kelly-Hayes M, et al Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996;27:1760-4
  • Christensen MC, Munro V. Ischemic stroke and intracerebral hemorrhage: the latest evidence on mortality, readmissions and hospital costs from Scotland. Neuroepidemiology 2008;30:239-46
  • Cotte FE, Chaize G, Gaudin AF, et al. Burden of stroke and other cardiovascular complications in patients with atrial fibrillation hospitalized in France. Europace 2016;18:501-7
  • Commissie Farmaceutische Hulp. Farmaco Economisch rapport dabigatran etexilaat (Pradaxa®). Diemen (The Netherlands): Commissie Farmaceutische Hulp; 2011
  • de Leest H, van Dieten H, van Tulder M, et al. Costs of treating bleeding and perforated peptic ulcers in The Netherlands. J Rheumatol 2004;31:788-91
  • Parker DR, Luo X, Jalbert JJ, et al. Impact of upper and lower gastrointestinal blood loss on healthcare utilization and costs: a systematic review. J Med Econ 2011;14:279-87

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.